Compare Quest Diagnostics Inc (DGX) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PubMatic Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while PubMatic Inc trades at $17.52 (market cap $804.41M). The key difference: Quest Diagnostics Inc is far larger — about 32.6× PubMatic Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| DGX | PUBM | |
|---|---|---|
Market Cap | $26.21B | $804.41M |
Sector | Health | Technology |
52-Week High | $238.50 | $17.78 |
52-Week Low | $173.49 | $6.28 |
Enterprise Value | $31.97B | $707.54M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
PUBM trades at $17.18, down 3.27% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported a Q2 2026 earnings beat with 11% revenue growth, driven by mobile app and CTV segments, though it remains unprofitable with a negative net income margin. Recent news highlights strategic hires and product launches like AgenticOS to capitalize on AI in advertising.
The outlook is mixed: strong revenue growth and analyst buy ratings support upside to the $20.83 consensus target, but profitability challenges and high valuation ratios pose risks. Investors should weigh the growth potential in high-margin segments against persistent losses and competitive pressures in the ad tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
